←
RedChip16,954 posts
RedChip avatar

RedChip

@RedChip

The World Leader in Small-Cap Investor Relations. This is not investment advice. Full disclosures: redchip.com/legal/disclosure…

◷ Joined March 2009▧ 4,544 Photos and videos
RedChip avatar
RedChip@RedChip·1h

Foremost Clean Energy (Nasdaq: $FMST): New Uranium Discovery at Turkey Lake Adds a Second Target Area Alongside Hatchet Lake Foremost Clean Energy (Nasdaq: FMST) discovered uranium in its first-ever drill program at the Turkey Lake project in Saskatchewan’s Athabasca Basin. Hole TL-26-02 returned 0.13% eU₃O₈ over 3.0 metres, including 0.29% over 0.5 metres. What matters most for investors is the location. The discovery sits outside the area historical drilling focused on, which could point to an entirely new mineralized trend on the property. Several similar untested targets remain nearby. Combined with the high-grade discovery at Hatchet Lake, Foremost now has two areas worth follow-up drilling. The next catalyst is chemical assay results, which are pending. Full press release: redchip.news/4zsxAT2

RedChip avatar
RedChip@RedChip·19h

Bimergen Energy (NYSE American: $BESS) posted its second straight profitable quarter. Q3 net income rose 50% from Q2 to $2.4 million, on revenue of $3.0 million. The company sold stakes in three Texas battery storage projects while keeping 7.5% of each for long-term upside. With about 2.0 GW across 33 projects still in development, Bimergen sees more opportunities to turn its pipeline into revenue. Full press release: redchip.news/4C94omD #Bimergen #BESS #BatteryStorage #EnergyStorage #CleanEnergy #GridReliability #SmallCapStocks #RedChip

Post attachment
RedChip avatar
RedChip@RedChip·Nov 17

Greenwich LifeSciences (Nasdaq: $GLSI): Phase III Breast Cancer Immunotherapy Trial to Be Featured at Major Oncology Conference December 9 Greenwich LifeSciences (Nasdaq: GLSI) will present two posters on its Phase III FLAMINGO-01 trial at the San Antonio Breast Cancer Symposium on December 9. The global trial is evaluating GLSI-100, an FDA Fast Track-designated immunotherapy designed to prevent breast cancer recurrence following surgery. Earlier Phase II results showed no recurrences among fully immunized patients, providing the foundation for the Phase III program, which had expanded to more than 170 clinical sites across the U.S. and Europe as of July 2026. The upcoming presentations will put the program before leading oncology researchers at a conference expected to attract approximately 10,000 healthcare professionals. Both posters are authored by the trial's Steering Committee, with additional details expected during the conference. Full press release: redchip.news/3WMpCqi

RedChip avatar
RedChip@RedChip·Nov 17

⏰ One Week Away: Nord Precious Metals (OTCQB: $NPMMF, TSXV: NTH) Live Investor Webinar, Tuesday, November 24 at 4:15 PM ET The Nord webinar is one week away. Most junior miners have to discover, define and develop a deposit before they can generate revenue. Nord already controls silver in historic tailings at surface, along with existing processing infrastructure, giving it a potentially faster and less capital-intensive route to production. 📈 What’s driving the story: Historic tailings at surface offer a potentially lower-cost, faster path to production than conventional mine development Nord operates TTL Laboratories, the Cobalt Camp’s only permitted high-grade milling facility It owns a 600-tonne-per-day modular gravity plant intended for tailings recovery Future production cash flow could help fund exploration and reduce reliance on equity financing Upcoming catalysts include permitting, metallurgical studies, project economics and plant commissioning Secure your seat today to hear management’s view of the road ahead. 🔗 Register here: redchip.news/4fabXQ3 #NPMMF #NTH #NordPreciousMetals #Silver #SilverStocks #Mining #JuniorMining #Ontario #OTCQB #InvestorWebinar

Post attachment
RedChip avatar
RedChip@RedChip·Nov 17

📣 Two Days Out: FibroBiologics (NASDAQ: FBLG) Live Investor Webinar, Thursday, November 19 at 4:15 PM ET If you haven’t registered yet, now is the time. On Thursday, management will discuss FibroBiologics’ fibroblast-based pipeline and recent progress in intellectual property and preclinical research. It’s a direct chance to ask about clinical plans, pipeline priorities and the path forward. 🎯 Topics to hear about: The company’s clinical-stage pipeline in chronic disease Its degenerative disc disease program, which uses allogeneic, cartilage-forming cells designed to restore what the disc has lost Its oncology approach: fibroblasts engineered as tumor-homing delivery vehicles A patent portfolio of more than 270 issued and pending patents, including the newly granted European patent Indications spanning wound healing, multiple sclerosis, psoriasis, orthopedics and human longevity Register now so you can join the live presentation and Q&A. 🔗 Register here: redchip.news/4fchsh2 #FBLG #FibroBiologics #CellTherapy #Fibroblasts #RegenerativeMedicine #WoundHealing #Biotech #NasdaqStocks #InvestorWebinar #SmallCapInvesting

Post attachment
RedChip avatar
RedChip@RedChip·Nov 16

More than 100 million people over age 65 get the seasonal flu each year, and many of them need an alternative to the vaccine. Traws Pharma (Nasdaq: TRAW) is developing an oral medication to prevent seasonal flu, which the company says would be the first of its kind and which targets a $5 billion market. The company is led by an experienced drug developer and a former director of the CDC. The key catalyst for investors is Phase 2 clinical data, which is expected in the near term. Learn more: redchip.com/stocks/TRAW #TrawsPharma #TRAW #Nasdaq #Biotech #Influenza #FluSeason #FluPrevention #InfectiousDisease #ClinicalTrials #BiotechStocks #SmallCapStocks #MicroCap #RedChip

0:30
RedChip avatar
RedChip@RedChip·Nov 16

Cancer claims about 10 million lives a year, and an estimated 90% of those deaths come from metastatic cancer. TransCode Therapeutics (Nasdaq: $RNAZ), led by scientists from Harvard Medical School, is developing a treatment for metastatic cancer. In a Phase 1 trial, its lead drug candidate showed favorable safety and tolerability, and the disease stabilized in some patients. It is now in a Phase 2 trial in colorectal cancer, the next key step for the program. #TransCodeTherapeutics #RNAZ #Nasdaq #Biotech #Oncology #MetastaticCancer #ColorectalCancer #CancerResearch #ClinicalTrials #RNATherapeutics #BiotechStocks #SmallCapStocks #MicroCap #RedChip Learn more: redchip.com/stocks/RNAZ

0:30
RedChip avatar
RedChip@RedChip·Nov 16

BioVie (Nasdaq: $BIVI): Phase 2 Long COVID Data Identify Patient Groups That May Benefit Most From Bezisterim BioVie presented findings from its Phase 2 ADDRESS-LC trial at the 4th Long COVID International Conference in Nice, France. Exploratory analyses identified two biologically distinct patient groups with different responses to bezisterim. Patients with elevated inflammation showed statistically significant improvements in cognition, while those with low white blood cell levels showed promising effects on fatigue and post-exertional malaise. Bezisterim also reduced neuropeptide Y (NPY) levels by approximately 33% versus placebo, a statistically significant finding involving a biomarker added to the NIH's RECOVER prioritization list. BioVie says the results support a more targeted approach to future Long COVID trials. The study was fully funded by a $13.13 million U.S. Department of War award, and bezisterim's safety profile was comparable to placebo. Full press release: redchip.com/stocks/BIVI

RedChip avatar
RedChip@RedChip·Nov 16

Venu Holding Corporation (NYSE American: $VENU): Assets Surge 59% to $587.6 Million as Two New Amphitheaters Prepare to Open Venu Holding (NYSE American: VENU) reported Q3 2026 results as it prepares to bring two major entertainment venues online. Total assets climbed 59% from year-end 2025 to $587.6 million. Regent Bank Amphitheater in Oklahoma is scheduled to open on New Year's Eve, while Sunset Amphitheater McKinney in Texas is expected to be completed in Q1 2027. Cumulative Luxe FireSuite and Aikman Club sales have surpassed $300 million, with McKinney's Luxe FireSuites 95% sold ahead of opening. At Ford Amphitheater, average revenue per show rose nearly 10% to $609,000. VENU also closed a $60 million sale-leaseback to help fund McKinney's completion while retaining ownership of the amphitheater. With more than 110 event holds across its portfolio for 2027, management expects a meaningful increase in ticketing, food and beverage, and sponsorship revenue as the new venues begin operating. Full press release: redchip.news/4zsO4uy

RedChip avatar
RedChip@RedChip·Nov 16

Vector Science and Therapeutics (TSXV: $PAIN): Dr. James Andrews and Former HHS Secretary Tommy Thompson to Unveil Major Peptide-Related Medical Development November 18 Sports medicine pioneer Dr. James Andrews and Vector Chairman Tommy G. Thompson, former U.S. Secretary of Health and Human Services, will host a livestreamed briefing on November 18 at 11:00 a.m. CST (12:00 p.m. ET) to announce what the company describes as a major medical development involving peptides in the United States. Vector is advancing targeted drug delivery technologies and pharmaceutical-grade prescription peptides for sports medicine, regenerative medicine, pain management and wound care. Its portfolio includes advanced transdermal delivery, precision catheter systems and smart wound care technologies, with peptides manufactured under pharmaceutical quality standards. Learn more: redchip.news/4C3Q2nB

RedChip avatar
RedChip@RedChip·Nov 16

⏰ One Week Away: Gunnison Copper ($GUNN) Live Investor Webinar, Monday, November 23 at 4:15 PM ET The Gunnison Copper webinar is one week away. Few U.S. copper developers have both a producing mine and a permitted development project. Management will explain how the company plans to repeat its Johnson Camp execution at its flagship Gunnison project. 📈 What’s driving the story: Johnson Camp went from final investment decision to production in under 18 months Built for about $200M with partner Rio Tinto Management plans to bring the same pace to the flagship Gunnison project An existing permit means the project faces less of the biggest risk for new U.S. mines Secure your seat today to hear management’s view of the road ahead. 🔗 Register here: redchip.news/4C2qrvk #GUNN #GunnisonCopper #Copper #CopperMining #Arizona #CriticalMinerals #MiningStocks #NYSEAmerican #InvestorWebinar #SmallCapInvesting #RedChip

Post attachment
RedChip avatar
RedChip@RedChip·Nov 13

📣 Nord Precious Metals (OTCQB: $NPMMF, TSXV: NTH) Live Investor Webinar: Tuesday, November 24 at 4:15 PM ET Nord Precious Metals is advancing a district-scale silver portfolio in Ontario’s historic Cobalt-Gowganda camp, one of the world’s highest-grade primary silver regions. Its strategy has two tracks: a potential near-term path to silver production from historic tailings already at surface, and long-term exploration at the high-grade Castle East discovery. Mark your calendar to hear management outline both. 🔍 Why investors are watching: An updated NI 43-101 indicated resource of 2.814M ounces of silver grading 47.4 g/t at the Gowganda tailings project A historical inferred resource of 7.56M ounces of silver grading 8,582 g/t at Castle East Assets with more than 57 million ounces of historical silver production Engineering and permitting advancing under Ontario’s streamlined Mineral Recovery Permit framework A 560-metre surface gold trend that adds potential upside beyond silver Register now to reserve your spot for the live presentation and Q&A. 🔗 Register here: redchip.news/4fabXQ3 #NPMMF #NTH #NordPreciousMetals #Silver #SilverStocks #Mining #JuniorMining #Ontario #OTCQB #InvestorWebinar #RedChip

Post attachment
RedChip avatar
RedChip@RedChip·Nov 13

Nova Minerals Corp. (NYSE American: $NVA): Final Antimony Permits Secured as Company Advances Toward 2027 Pilot Production in Alaska Nova Minerals Corp. reported third-quarter 2026 results and continued progress at its Estelle Gold and Critical Minerals Project in Alaska. After the quarter ended, Nova received all final state approvals for its three-year pilot-scale antimony project, which covers mining, ore processing and refining. About 500 tons of processing and refining equipment has been delivered to Port MacKenzie, and early earthworks are underway. The antimony program is funded by a $43.4 million U.S. Department of War award, and Nova has received about $23.9 million of it so far. On the gold side, Nova completed an extensive 2026 drilling program and continues the technical work for its Gold Pre-Feasibility Study. CEO Christopher Gerteisen said the permits bring Nova a significant step closer to establishing a secure U.S. domestic antimony supply chain. Full press release: redchip.news/4kPZa8Y

RedChip avatar
RedChip@RedChip·Nov 13

Zeo Energy (Nasdaq: $ZEO): Energy Affordability Moves to Center Stage After 2026 Midterms in Zeo’s Core Markets Zeo Energy (Nasdaq: ZEO) reports that electricity affordability emerged as a major issue in its five core markets—Florida, Pennsylvania, Ohio, Texas and Virginia—following the November 3 midterm elections. Winning candidates from both parties emphasized expanding power generation and protecting households from rising electricity costs, including those associated with data center demand. Zeo sees these priorities supporting demand for residential solar while creating opportunities for its expansion into commercial energy generation and long-duration storage for data centers and other large power users. At the federal level, industry analysts see potential for an extension of solar tax credits in 2027, which could further support the sector. CEO Tim Bridgewater said the election results align with Zeo's strategy of helping homeowners control energy costs while providing power solutions for energy-intensive businesses. Full press release: redchip.com/stocks/ZEO

RedChip avatar
RedChip@RedChip·Nov 13

Greenwich LifeSciences (Nasdaq: $GLSI): CEO Interview Airs on RedChip’s Small Stocks, Big Money™ Show on Bloomberg TV and CNBC This Weekend Greenwich LifeSciences (Nasdaq: GLS) CEO Snehal Patel joins the RedChip Small Stocks, Big Money™ show to discuss GLSI-100. The immunotherapy is designed to prevent HER2-positive breast cancer from returning after surgery. In an earlier Phase IIb trial, GLSI-100 showed about an 80% reduction in recurrence. Patel discusses early observations from the company’s ongoing Phase III FLAMINGO-01 trial, which could support expanding the treatment to a broader patient population. He also covers the trial’s expansion across the U.S. and Europe, progress in commercial-scale manufacturing and upcoming interim analyses. The interview airs on Bloomberg TV Saturday, November 14, at 7:00 p.m. ET and on CNBC Sunday, November 15, at 11:30 a.m. ET. Watch the full interview: redchip.news/48j2CBH

RedChip avatar
RedChip@RedChip·Nov 13

Venu Holding Corporation (NYSE American: $VENU): Strengthens Music Industry Presence Through Billboard Disruptor Award at Live Music Summit Venu Holding Corporation (NYSE American: VENU) joined Billboard in honoring Jorge Juárez, CEO of Westwood Entertainment and founder of Novus Media, with the Billboard Disruptor Award presented by VENU at the 2026 Billboard Live Music Summit in Los Angeles. VENU Founder, Chairman and CEO J.W. Roth presented the award, which recognizes innovators reshaping live entertainment. Juárez was honored for expanding Música Mexicana's reach, including helping Carín León perform at Coachella, Stagecoach and the Grand Ole Opry. The collaboration highlights VENU's growing industry presence as it expands its portfolio of premium, fan-focused entertainment venues across the U.S. VENU's broader strategic relationships include AEG Presents, Troy Aikman, Aramark Sports + Entertainment and other major entertainment brands. Full press release: redchip.news/4exQ1OH